The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistanc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wiesmann, Frank, Vachta, Jan, Ehret, Robert, Walter, Hauke, Kaiser, Rolf, Stürmer, Martin, Tappe, André, Däumer, Martin, Berg, Thomas, Naeth, Gudrun, Braun, Patrick, Knechten, Heribert
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2011
Materias:
Short Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049128/
https://ncbi.nlm.nih.gov/pubmed/21314993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-6405-8-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares